CS
ANIP icon

Credit Suisse’s ANI Pharmaceuticals ANIP Stock Holding History

Credit Suisse’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.17M Hold
31,453
– – ﹤0.01% 1797
2023
Q4 		$1.73M Buy
31,453
+5,365
+21% +$295K ﹤0.01% 1977
2023
Q3 		$1.51M Buy
26,088
+3,536
+16% +$204K ﹤0.01% 2004
2023
Q2 		$1.21M Buy
22,552
+5,115
+29% +$227K ﹤0.01% 2254
2023
Q1 		$693K Buy
17,437
+5
+0% +$211 ﹤0.01% 2543
2022
Q4 		$701K Buy
17,432
+3,411
+24% +$128K ﹤0.01% 2577
2022
Q3 		$450K Buy
14,021
+70
+0.5% +$2.4K ﹤0.01% 2845
2022
Q2 		$414K Sell
13,951
-748
-5% -$21.6K ﹤0.01% 2957
2022
Q1 		$413K Sell
14,699
-196
-1% -$7.31K ﹤0.01% 3079
2021
Q4 		$688K Sell
14,895
-12,646
-46% -$543K ﹤0.01% 3600
2021
Q3 		$904K Sell
27,541
-2,167
-7% -$67.4K ﹤0.01% 3424
2021
Q2 		$1.04M Buy
29,708
+2,798
+10% +$95.2K ﹤0.01% 3353
2021
Q1 		$972K Sell
26,910
-4,199
-13% -$131K ﹤0.01% 3344
2020
Q4 		$904K Buy
31,109
+3,361
+12% +$96.3K ﹤0.01% 3403
2020
Q3 		$782K Sell
27,748
-15,160
-35% -$451K ﹤0.01% 3111
2020
Q2 		$1.39M Buy
42,908
+26,390
+160% +$946K ﹤0.01% 2674
2020
Q1 		$672K Buy
16,518
+8,146
+97% +$433K ﹤0.01% 2947
2019
Q4 		$517K Buy
8,372
+1,550
+23% +$103K ﹤0.01% 3546
2019
Q3 		$497K Buy
6,822
+273
+4% +$20.4K ﹤0.01% 3441
2019
Q2 		$538K Sell
6,549
-701
-10% -$49.9K ﹤0.01% 3357
2019
Q1 		$512K Sell
7,250
-407
-5% -$23.9K ﹤0.01% 3313
2018
Q4 		$344K Buy
7,657
+1,591
+26% +$83.4K ﹤0.01% 3457
2018
Q3 		$343K Sell
6,066
-2,593
-30% -$159K ﹤0.01% 3463
2018
Q2 		$578K Buy
8,659
+2,028
+31% +$127K ﹤0.01% 3352
2018
Q1 		$385K Sell
6,631
-888
-12% -$56.4K ﹤0.01% 3477
2017
Q4 		$485K Sell
7,519
-4,136
-35% -$257K ﹤0.01% 3448
2017
Q3 		$612K Buy
11,655
+5,921
+103% +$282K ﹤0.01% 3421
2017
Q2 		$269K Sell
5,734
-5,936
-51% -$286K ﹤0.01% 3516
2017
Q1 		$578K Sell
11,670
-2,328
-17% -$131K ﹤0.01% 3190
2016
Q4 		$847K Buy
13,998
+1,810
+15% +$111K ﹤0.01% 3139
2016
Q3 		$809K Sell
12,188
-10,721
-47% -$671K ﹤0.01% 3125
2016
Q2 		$1.28M Sell
22,909
-380
-2% -$18.5K ﹤0.01% 2708
2016
Q1 		$783K Sell
23,289
-10,625
-31% -$360K ﹤0.01% 2911
2015
Q4 		$1.53M Buy
33,914
+21,859
+181% +$941K ﹤0.01% 2473
2015
Q3 		$477K Sell
12,055
-11,960
-50% -$680K ﹤0.01% 3428
2015
Q2 		$1.49M Buy
24,015
+9,211
+62% +$548K ﹤0.01% 2806
2015
Q1 		$926K Sell
14,804
-912
-6% -$55.5K ﹤0.01% 3034
2014
Q4 		$886K Buy
15,716
+1,472
+10% +$64.9K ﹤0.01% 3243
2014
Q3 		$403K Sell
14,244
-24,828
-64% -$744K ﹤0.01% 3781
2014
Q2 		$1.35M Buy
39,072
+18,621
+91% +$584K ﹤0.01% 3045
2014
Q1 		$640K Buy
+20,451
New +$543K ﹤0.01% 3522

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's ANIP Position: Q1 2024 in Review

Credit Suisse held its ANI Pharmaceuticals (ANIP) position steady in Q1 2024 at 31,453 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Credit Suisse first reported a position in ANIP in Q1 2014 and has held it in 41 quarters since. 200 funds tracked by Wall St. Rank hold ANIP as of Q1 2024.

  • Credit Suisse held 31,453 shares of ANI Pharmaceuticals worth $2.17M as of Q1 2024.
  • Credit Suisse left its ANI Pharmaceuticals share count unchanged in Q1 2024.
  • ANI Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1797 holding.
  • Credit Suisse first reported a position in ANI Pharmaceuticals in Q1 2014 and has held it in 41 quarters since.
  • 200 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.